Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 6, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration...
-
Aug 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial launch of a major new store brand...
-
Aug 16, 2012- Full-year revenue from continuing operations increased $418 million, or 15%, to a record $3.2 billion.
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012. (Logo:...
-
Aug 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on September...
-
Aug 9, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Aug 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2012 on Thursday,...
-
Jun 27, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Jun 11, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Clobetasol propionate...
-
Jun 8, 2012
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer Judy Brown will present at the...
-
Jun 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 30, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval to Tris Pharma for its...
-
May 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and Chief Executive Officer, Joseph C. Papa, will present at the...
-
May 22, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 18, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at...
-
May 8, 2012-- Fiscal third quarter revenue from continuing operations increased $86 million, or 13%, to $778 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 31, 2012. (Logo:...
-
May 3, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on June 19,...
-
Apr 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...
-
Apr 12, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...
-
Mar 21, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...
-
Mar 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...
-
Mar 1, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and...
-
Feb 28, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO Joseph Papa will present at the RBC Capital Markets' Healthcare Conference on...
-
Feb 14, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to...